Literature DB >> 11089696

Comparison of Gadomer-17 and gadopentetate dimeglumine for differentiation of benign from malignant breast tumors with MR imaging.

H E Daldrup-Link1, D M Shames, M Wendland, A Mühler, A Gossmann, W Rosenau, R C Brasch.   

Abstract

RATIONALE AND
OBJECTIVES: This study compared gadopentetate dimeglumine (molecular weight, 0.5 kD), a standard contrast medium, and Gadomer-17 (apparent molecular weight, approximately 35 kD), a new, clinically applicable, large-molecular contrast medium, with respect to their microvascular characterizations of experimentally induced breast tumors at magnetic resonance (MR) imaging.
MATERIALS AND METHODS: A spectrum of breast tumors, benign through highly malignant, was induced in Sprague-Dawley rats (n = 30) by intraperitoneal administration of N-ethyl-N-nitrosourea (ENU), a potent carcinogen. All animals underwent three-dimensional spoiled gradient-recalled MR imaging, with precontrast imaging and dynamic postcontrast imaging after injection of gadopentetate dimeglumine (0.1 mmol/kg) and Gadomer-17 (0.03 mmol/kg), administered in a random order at a 24-hour interval. Several microvascular parameters were compared: the endothelial transfer coefficient (K(PS)), a measure of microvascular permeability; the fractional plasma volume (fPV), and the plasma equivalent volume. Each MR imaging parameter was correlated with histopathologic findings.
RESULTS: With Gadomer-17, the mean values for K(PS) and fPV were significantly greater in carcinomas than in fibroadenomas (P < .004 and .04, respectively). With gadopentetate dimeglumine, the mean values for fPV and PEV were significantly greater in carcinomas (P <. 004 and .02, respectively). Because of the high variability within both fibroadenoma and carcinoma groups, however, there were no significant correlations between K(PS), fPV, or PEV and histopathologic tumor grade as indicated by the Scarff-Bloom-Richardson score, for either agent.
CONCLUSION: Although the K(PS) and fPV estimates obtained from dynamic MR imaging data with Gadomer-17 enhancement offer some potential for characterizing breast tumors, none of the quantitative microvascular parameters derived with either agent were significantly correlated with histopathologic tumor grade.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11089696     DOI: 10.1016/s1076-6332(00)80175-0

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  7 in total

1.  Discrimination of metastatic from non-metastatic mesorectal lymph nodes in rectal cancer using quantitative dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Xiao-Ping Yu; Lu Wen; Jing Hou; Hui Wang; Qiang Lu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-28

Review 2.  Promise and progress for functional and molecular imaging of response to targeted therapies.

Authors:  Renu M Stephen; Robert J Gillies
Journal:  Pharm Res       Date:  2007-03-24       Impact factor: 4.200

3.  In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model.

Authors:  Hans-Juergen Raatschen; Yanjun Fu; Robert C Brasch; Hubertus Pietsch; David M Shames; Benjamin M Yeh
Journal:  Invest Radiol       Date:  2009-05       Impact factor: 6.016

4.  MRI measurement of change in vascular parameters in the 9L rat cerebral tumor after dexamethasone administration.

Authors:  James R Ewing; Stephen L Brown; Tavarekere N Nagaraja; Hassan Bagher-Ebadian; Ramesh Paudyal; Swayamprava Panda; Robert A Knight; Guangliang Ding; Quan Jiang; Mei Lu; Joseph D Fenstermacher
Journal:  J Magn Reson Imaging       Date:  2008-06       Impact factor: 4.813

5.  Macromolecular Imaging Agents Containing Lanthanides: Can Conceptual Promise Lead to Clinical Potential?

Authors:  Joshua Bryson; Jeffrey W Reineke; Theresa M Reineke
Journal:  Macromolecules       Date:  2012-11-13       Impact factor: 5.985

Review 6.  High-field small animal magnetic resonance oncology studies.

Authors:  Louisa Bokacheva; Ellen Ackerstaff; H Carl LeKaye; Kristen Zakian; Jason A Koutcher
Journal:  Phys Med Biol       Date:  2013-12-30       Impact factor: 3.609

7.  Novel nano-sized MR contrast agent mediates strong tumor contrast enhancement in an oncogene-driven breast cancer model.

Authors:  Per-Olof Eriksson; Emil Aaltonen; Rodrigo Petoral; Petter Lauritzson; Hideki Miyazaki; Kristian Pietras; Sven Månsson; Lennart Hansson; Peter Leander; Oskar Axelsson
Journal:  PLoS One       Date:  2014-10-08       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.